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Abstract
Background:Non-smallcelllungcancer (NSCLC) is a leadingcauseofcancerdeaths, andover 60%ofpatientspresentwith
advanced stages. Although polysaccharide peptides (PSP), isolated from the fungus Coriolus versicolor, have been re-
ported to have anti-tumor effects, its clinical efficacy has not been properly evaluated.Methods:Double-blind placebo-
controlled randomized study to evaluate the effects of 28-day administration of PSP (Windsor Pharmaceutical, Hong
Kong) on patients, who had completed conventional treatment for advanced NSCLC. Results:Thirty-four patients, with
no significantdifference in their baseline demographic, clinical or tumor characteristics, or previous treatment regimes
(P40.05), wererecruitedinto eachofthe PSPandcontrolarms.After 28-day treatment, therewas a significantimprove-
ment in blood leukocyte andneutrophil counts, serum IgG and IgM, andpercentof body fat among the PSP, butnotthe
control, patients (Po0.05). Although the evaluable PSP patients did not improve in NSCLC-related symptoms, there
were significantly less PSP patients withdrawn due to disease progression, than their control counterparts (5.9 and
23.5%, respectively; P=0.04; OR 4.00).There was no reported adverse reaction attributable to the trial medications.
Conclusion: PSP treatment appears to be associatedwith slowerdeterioration in patientswith advanced NSCLC.r 2003
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Lung cancer is a leading cause of cancer deaths in most
parts of theworld, andover 60%ofpatientspresentwith
advanced stage IIIB and IV disease (1,2). Non-small cell
lung cancer (NSCLC) accounts for about 80% of all pri-
mary lung cancers (1).Yun-zhi (Coriolus versicolor) is a fun-
gus, which is believed by the Orientals to have both
direct and symptom-alleviating e¡ects in the treatment
of cancer (3). A group of polysaccharide peptides (PSP)
has been isolated from the mycelium of Yun-zhi, which
has been reported to show anti-tumor e¡ects in vitro
(4,5). Despite anecdotal experience and in vitro data to
suggest its clinical e⁄cacy (3,6^10), there has not been
any published study in the English literature on theReceived 20 August 2002, accepted in revised form 5 November 2002
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(852) 2872 5828; E-mail: kwttsang@hku.hke¡ects of PSP in patients with lung cancer. We have,
therefore, performed this double-blind placebo-con-
trolled randomized study to evaluate the palliative ef-
fects of PSP on patients with advancedNSCLC.
MATERIALSANDMETHODS
Study design and overview
This pilot study is a phase II double-blind placebo-con-
trolled randomized (block of 4) trial on patients with ad-
vanced NSCLC. Patients were recruited from a
university-based tertiary center, which has an estab-
lished interest in the treatment of NSCLC. Eligible pa-
tients were randomized (block of 4) by picking a sealed
envelop, which contained a card depicting the treatment
bottle number, from a sealed box, at baseline to receive
three capsules (340mg each) of puri¢ed Yun-zhi PSP
(Windsor Pharmaceutics,HongKong) or identical place-
bo (350mg crystallized sucrose each) capsules three
times daily for 4 weeks (28 days) (8).Clinical and labora-
tory evaluation of patients was performed at baseline
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the study was to evaluate the e¡ect of oral administra-
tion of Yun-zhi PSPonNSCLC-speci¢cmorbidity, and the
secondary objective was to determine the safety pro¢le
of this preparation.
Eligibility
Patient enrollment commenced in December 1999 and
ended in April 2001. Inclusion criteria were: Karnofsky
performance scale Z60, life expectancy Z12 weeks,
TNM stage III or IV (11), andhistologically or cytologically
proven inoperable NSCLC with at least one bi-dimen-
sionally measurable lesion. Measurable lesions included
super¢cial lymph nodes or skin nodules measured di-
rectly (Z2010mm2) or by ultrasound (Z10
10mm2), pulmonary nodules on chest radiograph
(Z1010mm2) or lesions on computed tomography or
magnetic resonance imaging (Z1010mm2). Bone me-
tastases, pleural e¡usion, ascites, andpericardial e¡usion
were not considered as measurable lesions. Previous
radiotherapy was permitted if completed at least 4
weeksprior to study, and ifmeasurable diseasewas com-
pletely outside the radiation portal. Similarly, previous
chemotherapy was permitted if completed at least 4
weeks prior to study. Laboratory values for eligible pa-
tients included neutrophils Z2.0109 l1, platelets
Z100109 l1, hemoglobinZ10g/dl, totalbilirubinothe
upper limit of normal (ULN), aspartate transaminase
(AST) and alanine transaminase (ALT)o2.5ULN, al-
kaline phosphatase (ALP)o5ULN, and serum creati-
nineo140mmol/l (or creatinine clearanceZ60ml/min).
Exclusion criteria included pregnancy, lactating and
breastfeeding, presence of other malignancies, mental
confusion, or disagreement by the next of kin or carer
to participate.Written informed consent was obtained
from all patients, and the institutional ethics committee
had approved the study protocol.
Evaluation of toxicity and response
All patients were evaluated at baseline to ensure that
they were stable in their general condition and NSCLC-
speci¢c morbidity for 4 weeks before recruitment into
the study. Karnofsky performance scale (KPS; ranges
from 0 to 100, where 0 equals dead and 100 means nor-
mal) was determined for each patient. Hematological
and biochemical screening tests (electrolytes, liver and
renal function tests), and serum immunoglobulin A, G
and M were assessed at baseline and 4 weeks.Toxicities
were graded according to the NCI common toxicity cri-
teria (grade 0^4). The weight (kg) and height (m) were
determined between 9 and11a.mwith the subject bare-
foot and dressed in very light clothing. From these, the
body mass index was calculated as the ratio of weight-
to-height squared for each subject (12). The percentageof body fat was determined by using a commercially
available electronic device (model TBF-300, TANITA
Corporation, Tokyo, Japan), by the bioelectrical impe-
dance analysis technique (13).The baseline investigations
for tumor bulk assessment including chest radiography
and clinical examination were repeated after 4 weeks of
treatment. Evaluation of tumor response was based on
the WHO criteria after 4 weeks treatment (14). Com-
plete response (CR) was de¢ned as the disappearance
of all known malignant disease. Partial response (PR)
was de¢ned as a decrease of at least 50% in the sum total
perpendicular diameters of the largest measurable le-
sions. Stable disease or no change (NC) was ao50% de-
crease or o25% increase in lesion size, whereas
progressive disease (PD) was a425% increase. Patients
with disease progression were not withdrawn from the
study until they themselves requested to do so, and only
on grounds of inability (either on physical or psychologi-
cal grounds or both) to attend the research clinic even
with ambulance pick up and nursing escort. All patients
were evaluated for toxicity as soon as they entered the
study. Patients were required to have a minimum of 2
weeks treatment to be evaluable for response.
Statistical analysis
For continuous data, summary statistics including fre-
quency (n), mean and standarddeviationwere expressed.
Within-group comparisons were performed with t-test
or Wilcoxon signed rank test where appropriate. Be-
tween-group comparisons were performed with t-test,
Mann^Whitney U-test, or chi-square where appropri-
ate. Odds ratio was determined by calculating the odds
of exposure in those with and without the end-point.
The analysis was performedusing the SPSSs10.0Version
package (SPSS Inc., Chicago, IL, U.S.A). A P value of less
than 0.05 was taken as statistically signi¢cant.
Intent-to-treat analysis was not performed as there
were only two visits, and the clinical circumstances did
not permit re-assessment of tumor response or repeat-
ing of blood taking on the patients already withdrawn
from the study (refer to results section).
RESULTS
Demographic data and cilinical
characteristics
Thirty-four stable patients were recruited into each of
the treatment arms (Table1).The two arms did not di¡er
in their previous treatment with chemotherapy, radio-
therapy or surgery, Karnofsky performance scale, or
TNM staging (P40.05), although the PSP patients were
signi¢cantly older than their counterparts (Po0.05, Ta-
ble1).Our chemotherapyregimewas six 3-weekly cycles
of paclitaxol and carboplatin for all those who under-
went this treatment.Of the 24 patients in the PSP group
TABLE 1. Demographic data ofthe 68 patientswithnon-small cell lungcancer
Parameters PSP Placebo P-value
Gender (M:F) 23:11 22:12 0.79
Age (mean, SD, range) 61.29,11.3, 39^82 55.26,10.7, 34^75 0.03
Weight (mean, SD, range) 54.99,8.3, 36^74 59.86,11.4, 28^76.5 0.05
Karnofskyperformance state (mean, SD, range) 86.76,7.27,70^100 86.47,7.74,60^90 0.87
Staging (TNM)
IIIA 1 (2.9%) 1 (2.9%) 0.88
IIIB 15 (44.1%) 13 (38.2%)
IV 18 (52.9%) 20 (58.8%)
Treatmentreceivedbefore study
None 6 (17.6%) 4 (11.8%) 0.49
Chemotherapy 24 (70.6%) 26 (76.5%) 0.58
Radiotherapy 17 (50) 16 (47.1%) 0.81
Surgery 2 (5.9%) 2 (5.9%) 1.00
P values obtained by using chi square test. Chemotherapy regime was six 3-week cycles of paclitaxel and carboplatin.
PSP=Yun-zhipolysaccharide peptide.
620 RESPIRATORYMEDICINEwhoreceivedchemotherapy, 6, 5, and13 caseshadpartial
response, stable disease, and disease progression after
treatment to chemotherapy, which were not signi¢-
cantly di¡erent from the 26 placebo patients (8, 5, and
13, respectively, P=0.64). All the patients had NSCLC on
histological (n=40) or cytological (n=28) examination of
appropriate tissue including bronchial biopsies, periph-
eral lymph node biopsies, transbronchial biopsies, or
bronchoalveolar lavage.The tumor cell-types were ade-
nocarcinoma (n=39), squamous cell cancer (n=15), or
classi¢ed as ‘‘non-small cell lung cancer’’ (n=14) by the re-
porting specialist pathologist. All the patients had 100%
compliance, as con¢rmed by home record charts and
capsule counts.
None of thepatients hadreported any adverse clinical
reactions to either placebo or PSP.There was no di¡er-
ence in the NSCLC-speci¢c symptoms between the two
treatment groups at baseline or after 4 weeks of treat-
ment, although PSP patients, butnot their counterparts,
had signi¢cantly less alopecia after 4 weeks (Table 2,
P=0.008).
Blood test parameters (Table 3)
Therewere no signi¢cantchanges in liver or renal indices
between the treatment groups at baseline or post-treat-
ment (P40.05). However, there was a signi¢cant in-
crease in the level of IgG and IgM after 4-week
treatment with PSP (P=0.002 and 0.01, respectively), but
notwith placebo (P=0.57 and 0.31).Between-group com-
parison also showed a signi¢cantly higher IgG and IgMlevels in the PSP, compared with the placebo, group
(P=0.02 and 0.04). There was no signi¢cant di¡erence in
the levels of IgAbefore or after treatmentin either treat-
ment group (P40.05). Although there was a trend for
hemoglobin to rise after 4-week treatmentwith PSP, this
was not statistically signi¢cant (P=0.08).Total leukocyte
and neutrophil counts increased signi¢cantly after PSP
(P=0.003 and 0.005, respectively), but decreased signi¢-
cantly after placebo treatment (P=0.006 and 0.01, respec-
tively).
Body mass index was not signi¢cantly di¡erent be-
tween baseline and post-treatment data for both treat-
ment groups (P40.05). There was a signi¢cant increase
in body fat content (%) after PSP, but not placebo, treat-
ment (P=0.02 and40.05, respectively,Table 3).However,
post-treatment body fact contents (%) were only mar-
ginally di¡erent between the two treatment groups
(P=0.08).
Tumor response and clinical progress
Tumor response was evaluated on 58 patients, who at-
tended reassessment at 4-week (PSP n=32 and placebo
n=26, respectively).Tumor response rate was evaluated
based on assessment of tumor dimensions using radio-
graphs on 53 (PSP n=31 and placebo n=22) and lymph
node on 5 (PSP n=1 and placebo n=4) patients. None of
the patients in either treatment arm was found to have
complete or partial clinical response. Of the remaining
evaluable patients, 25 and 20 patients in the PSP and pla-
cebo arms were found to have no signi¢cant changes in
TABLE 2. Symptoms at baseline and 4 week after treatmentwith PSP andplacebo
PSP Placebo
Numberof patients (%) Numberof patients (%)
Pre-Rx Post-Rx Pre-Rx Post-Rx
Cough 19 (55.9%) 16 (50%) 22 (64.7%) 19 (73.1%)
Sputum 17 (50%) 18 (56.3%) 19 (55.9%) 20 (76.9%)
Hemoptysis 6 (17.6%) 7 (21.9%) 5 (14.7%) 4 (15.4%)
Dyspnea 18 (52.9%) 16 (50.0%) 20 (58.8%) 10 (38.5%)
Chest pain 10 (29.4%) 6 (18.8%) 9 (26.5%) 9 (34.6%)
Bone pain 12 (35.3%) 13 (40.6%) 11 (32.4%) 10 (38.5%)
Pneumonia 0 (0%) 0 (0%) 0 (0%) 1 (3.8%)
Edema 3 (8.8%) 2 (6.3%) 3 (8.8%) 1 (3.8%)
Fatigue 18 (52.9%) 14 (43.8%) 18 (52.9) 9 (34.6%)
Hoarseness 6 (17.6%) 7 (21.9%) 8 (23.5%) 5 (19.2%)
Dysphagia 1 (2.9%) 1 (3.1%) 5 (14.7%) 1 (3.8%)
Nausea 5 (14.7%) 5 (15.6%) 7 (20.6%) 3 (11.5%)
Lackof appetite 8 (23.5%) 2 (6.3%) 8 (23.5%) 5 (19.2%)
Weight loss 10 (29.4%) 4 (12.5%) 7 (20.6%) 3 (11.5%)
Alopecia 9 (26.5%) 1 (3.1%)* 3 (8.8%) 1 (3.8%)
*P indicates a signi¢cantdi¡erencebetweenpre- andpost-treatmentdataonwithin-group comparison (Po0.05).Thereisno
signi¢cantdi¡erence in the post-treatmentdata betweenthe twotreatmentgroups (P40.05).
PSP=Yun-zhipolysaccharide peptide.
TABLE 3. Results of blood tests and other investigations onpatientswithnon-small cell lungcancer
PSP Placebo
Pre-RxMean (SD) Post-Rx Mean (SD) Pre-RxMean (SD) Post-Rx Mean (SD) +P
Hemoglobin (g/dl) 12.1 (1.40) 12.3 (1.23) 12.6 (1.59) 13.0 (1.45) 0.76
WBC (109/l) 6.4 (1.76) 7.3 (2.39)* 6.9 (5.22) 6.8 (3.06)* 0.73
Neutrophils (109/l) 4.4 (1.47) 5.2 (2.21)* 5.1 (5.34) 4.8 (2.85)* 0.77
Platelet (109/l) 264.7 (81.68) 267.8 (98.46) 245.0 (103.64) 243.8 (80.15) 0.97
Creatinine (mmol/l) 91.2 (13.15) 92.0 (13.28) 84.7 (13.74) 90.4 (17.95) 0.21
IgA (mg/dl) 268.3 (96.90) 280.6 (108.45) 305.2 (114.30) 292.4 (108.95) 0.85
IgG (mg/dl) 1468.8 (447.89) 1590.4 (504.89)* 1574.1 (741.27) 1532.8 (712.01) 0.02
IgM (mg/dl) 131.1 (63.15) 139.3 (64.32)* 142.7 (81.91) 126.9 (59.29) 0.04
Albumin (g/l) 40.6 (4.28) 40.5 (3.30) 40.6 (5.29) 41.2 (4.47) 0.91
Globulin (g/l) 37.4 (5.94) 38.3 (6.44) 37.8 (8.78) 36.8 (8.41) 0.20
Aspartate transaminase (U/l) 21.8 (8.48) 21.8 (6.28) 30.5 (28.94) 23.4 (6.10) 0.17
Alanine tansaminase (U/l) 16.8 (9.69) 16.6 (8.28) 37.7 (61.87) 21.3 (9.60) 0.20
Bodymass index 21.8 (3.52) 21.8 (3.42) 24.0 (3.61) 24.1 (3.72) 0.65
Body fatcontents (%) 22.5 (9.04) 23.3 (8.97)* 24.6 (7.85) 24.5 (8.20) 0.08
*Po0.05 whencomparedwithbaseline data fromwithin-group comparison. +P values obtainedonbetweengroup compar-
isons onpost-treatmentdata.
PSP=Yun-zhipolysaccharide peptide.
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¢ve patients in the PSP and placebo group had progres-
sive disease at 4 week assessment (P=0.72). Of these, 4
patients in each treatment arm had an increase in tumor
dimension 450% on radiographic assessment. One pa-
tient in the placebo group had enlargement of cervicallymphnode onphysical examination at 4week.Threepa-
tients in the PSP group were found to have new lesions,
manifesting as mass lesion on chest radiograph (n=1)
or cervical lymph node (n=2), while one patient in the
placebo group developed a new cervical lymph node
(P=0.62).
622 RESPIRATORYMEDICINEPatient withdrawal (Table 4)
Signi¢cantly more patients were withdrawn from the
placebo (n=8) than the PSP arm (n=2, P=0.04, OR 4.9,
95% CI 1.0^25.5), although the withdrawn patients had
no signi¢cant di¡erence in age (PSP 49.574.95; placebo
55.6713.48 yr; P=0.56), gender (M:F=2:0; 4:4), weight
(5373.53; 56.1715.9; P=0.80), KPS (80.0714.14;
81.3713.56; P=0.91) or tumor cell-type (adenocarcinoma
n=2; adenocarcinoma n=5, others n=3) at baseline. All
but one of the patients were withdrawn due to signi¢-
cant deterioration in general conditions, including mani-
festation of severe symptoms of cerebral metastases,
spinal cord compression, obstructive pneumonia, or de-
terioration in general state requiring hospitalization for
terminal care.Onepatient in theplacebo arm committed
suicide after progression of respiratory symptoms.There
was otherwise no other death in the study period.
DISCUSSION
Despite the widespread use of alternative and Chinese
Medicine in the treatment of patients with lung cancer,
there has not been a double-blind placebo-controlled
randomized clinical trial published in the English litera-
ture. Performing such trials using traditional Chinese or
alternative medicine is di⁄cult due to a non-uniformity
of prescription by di¡erent practitioners, lack of under-
standing on pharmacology, conceptual di¡erences be-
tween conventional Western and alternative medicine,
andperhapsmost importantly patient reluctance to par-
ticipate in double-blind and placebo-controlled studies.
In order to overcome some of these di⁄culties, we had
elected to undertake a short-term (4-week) study on
Yun-zhi PSP, a highly popular preparation manufactured
withGMP standards, onvery advancedpatientswho had
already completed conventional treatment. Our dataTABLE 4. Reasons of patientwithdrawal fromthe study
Drug Stage Gender Dayontreatment Reasons for withd
PSP IIIB M 21 General deteriorat
PSP IIIB M 30 General deteriorat
Placebo IV M 2 Brainmetastasis le
Placebo IIIB M 2 Severe right lower
requirementof oxy
Placebo IV F 7 Hospitalization at a
Placebo IV M 28 General deteriorat
Placebo IIIB F 3 General disease pr
£uctuatingconscio
Placebo IV F 4 Hospitalization at a
Placebo IV F 17 Paraplegia due to d
Placebo IV M 26 Committed suicide
PSP=Yun-zhipolysaccharide peptide.showed that 4-week administration of PSP was asso-
ciatedwith no apparent clinical or blood test adverse re-
actions.There was, however, signi¢cant improvement in
blood leukocyte and neutrophil counts, serum IgG and
IgM, and percent of body fat, which was not found
among placebo patients. As lung cancer patients with
lowering of IgG and IgM have shorter survival andmore
frequent pulmonary infections than their counterparts
(15), ourdemonstration of an improvementcouldbeben-
e¢cial to lung cancer patients. Although the remaining
PSP patients did not improve in NSCLC-related symp-
toms, signi¢cantly less PSP patients were withdrawn
from the study, comparedwithplacebo group, due todis-
easeprogression (5.9 and 23.5% respectively;P=0.04;OR
4.00).
PSP has a molecular weight of 100k and is prepared
from cultured mycelium of the COV-1 strain of Coriolus
versicolor (3). Chromatographic and spectral data from
infrarednuclearmagnetic andprotonresonance are con-
sistent with PSP being polypeptide (small protein) moi-
eties with attached polymeric monosaccharide chains,
and thus true proteoglycan (3). In general, very little if
any, information is available on thepharmacologyofmost
TCM and alternative preparations. The same applies to
Yun-zhi PSP, despite its popularity as a health food sup-
plement among cancer patients. This inadequacy in our
understanding of their pharmacokinetics and pharmaco-
dynamics will obviously strongly limit the clinical use of
Yun-zhi PSP and otherTCM or alternative preparations.
PSP appears to be e⁄cacious on ameliorating cancer
symptoms in patients with stomach and esophageal can-
cer, and NSCLC, and also alleviating the adverse e¡ects
of concomitant chemotherapy (3). In a phase III study
conducted in Shanghai, Beijing and other areas in China,
therewas a signi¢cantreduction in fatigue, anorexia, vo-
miting, and pain among such patients (n=189) treated
with PSP, but not on their counterparts (81 and 26%rawal from study
ion leading to patient beingcompletely bed-ridden
ion leading to patient beingcompletely bed-ridden
ading to patient beingcompletelybed-ridden
lobe pneumonia, and subsequent severe dyspnea and
gentherapy
notherhospital for terminal care due to general deterioration
ion leading to admissionto anotherhospital for terminal care
ogression and developmentof brainmetastasis leading to
us level.Commencementof brain radiotherapy.
notherhospital for terminal care due to general deterioration
evelopmentof spinal cord compression
CORIOLUSVERSICOLORPOLYSACCHARIDEPEPTIDE 623respectively, Po0.01) (7).However, our study is the ¢rst
controlled trial on PSP in a double-blind, placebo-con-
trolled and randomized fashion.
Themechanism(s) for thebene¢cial actions of PSP ob-
served on our patients, namely delaying of deterioration,
improvement of hematological indices and serum immu-
noglobulins, and increase in body fat contents, is unclear.
In addition, the underlying reason for the deterioration
in total leukoctye and neutrophil counts in the placebo
group is unclear, although this phenomenonmight simply
re£ect a general deterioration for these patients. How-
ever, in vitro studies suggest that PSP has direct anti-can-
cer as well as immunomodulatory e¡ects. PSP inhibits
growth of human hepatoma cell line and sarcoma180 in-
oculated in nudemice (6), restricts prostate tumorigenic
progression from the hormone-dependent to the hor-
mone-refractory state (8), and slows progression of a
herpes virus type 2-transformed murine tumor (H238)
model (16).There is also evidence that PSP administration
improves the immune status in animal tumor models.
PSP increasesT-lymphocyte proliferation in rats (9), and
enhances recoveryofmurine splenic dysfunction induced
by experimental gamma-ray irradiation (17). PSP also re-
duces cyclophosphamide-inducedmyelosuppression, and
increases IgG and interleukin-2 production in rats (18).
Although PSP does not increase the e⁄cacy of radio-
therapy in shrinking subcutaneously injectedC6 rat glio-
ma tumor, it nevertheless improves natural killer cell,
lymphocyte, and neutrophil counts in these animals (10).
Yun-zhi produces a number of proteins and proteogly-
cans, which appear to be bene¢cial to cancer patients.
PSK is also a proteoglycan of molecular weight approxi-
mately100k, and is extracted from strain CM-101of Cor-
iolus versicolor. PSK di¡ers from PSP in having fucose,
arabinose and rhamnose as its saccharide make-up. A
number of clinical trials had been performed, although
almost exclusively in Japan, on the e¡ects of PSK in can-
cer patients. PSK appears to extend the 5^8 year survi-
val and disease-free period for patients with resected
gastric, colorectal andesophageal cancers, andunresect-
able NSCLC (19^22). Another small polypeptide, of mo-
lecular weight of 10k, from Coriolus versicolor also
possesses potent cytotoxic e¡ect on human tumor cell
lines of HL-60, LS174-T, SMMU-7721, and SCG-7901 (4).
While conventional treatment for NSCLC includes
symptomatic relief, best supportive care, and radiother-
apy, chemotherapy is increasingly established as standard
mode of treatment. Platinum-based chemotherapy regi-
mens have signi¢cantly improved tumor response rates,
but have not made clinically meaningful improvement in
patient survival (23,24). Newer families of chemothera-
peutic agents, including the taxanes, gemcitabine, and
others, despite better tumor response rate, i.e. e⁄cacy
to reduce tumor size or progression rate, do not appear
to result in signi¢cant di¡erence in overall patient survi-
val (25^28).Many NSCLC patients also elect to undergotreatmentwith alternativemedicine, either as amainline
or after completion or failure of chemo- or/and radio-
therapy. The results of our study showing that Yun-zhi
PSP therapy was associated with signi¢cant slowing of
disease progression, detectable after 1 month of treat-
ment, provide encouraging evidence to pursue on
further studies of clinical e⁄cacy of alternativemedicine
in the treatment of these unfortunate patients.
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